Gossamer Bio
Market cap $67.5M 6.1M shares (10-Q, Nov 7, 2026) × $11.04 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- RT234 Inhaled Vardenafil trial start2027RT234 Inhaled Vardenafil trial start, 2027, routine
- 2030 Notes corporate updateMar 2, 20272030 Notes corporate update, Mar 2, 2027, routine
- seralutinib PAH FDA approval3Q 2027seralutinib PAH FDA approval, 3Q 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
vardenafil
RT234Capital (as filed)
- Cash
- $51.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$29.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $51.2M cash, runway into the first quarter of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-11-11 UPDATE: Gossamer Bio (GOSS) - The Mailroom Bet Becomes a Survival Bet
- 2026-09-23 UPDATE: Gossamer Bio (GOSS) - The NDA Is In. The Clock Is Running.
- 2026-09-09 UPDATE: Gossamer Bio (GOSS) - The Ratio Lands at 1-for-80
- 2026-08-22 UPDATE: Gossamer Bio (GOSS) - Somebody Just Underwrote the Hail Mary 🔒 Paid
- 2026-08-14 UPDATE: Gossamer Bio (GOSS) - The Debt Wall Didn’t Move to 2030. It Moved to March.
- 2026-07-28 UPDATE: Gossamer Bio (GOSS) - The Zombie Gets a Filing Path
- 2026-05-19 UPDATE: Gossamer Bio (GOSS) - The Debt Wall Comes Down, and So Does the Equity
- 2026-05-16 UPDATE: Gossamer Bio (GOSS) - The Zombie Files Its Q1, and a Class Action Arrives 🔒 Paid
- 2026-03-22 UPDATE: Gossamer (GOSS) - The Anatomy of a Biotech Death Spiral
- 2026-03-01 UPDATE: Gossamer Bio (GOSS) - The Enrichment Trap Springs Shut 🔒 Paid
- 2026-02-03 Gossamer Bio (GOSS): Scientific Deep Dive for Seralutinib 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Gossamer Bio, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-03 Watch Gossamer Bio (GOSS): Scientific Deep Dive for Seralutinib The biological mechanism is sound but clinical execution risk is high, relying on a post-hoc subgroup analysis from a failed Phase 2; wait for PROSERA results before taking a position.
- 2026-03-01 Avoid UPDATE: Gossamer Bio (GOSS) - The Enrichment Trap Springs Shut Phase 3 PROSERA missed its primary endpoint, confirming the Phase 2 subgroup signal was a statistical artifact; Chiesi terminated the partnership, and the convertible debt overhang makes the equity functionally worthless.
- 2026-03-22 Avoid UPDATE: Gossamer (GOSS) - The Anatomy of a Biotech Death Spiral Going-concern qualification, closed capital markets via Baby Shelf Rule, and Nasdaq delisting risk confirm Gossamer is now a distressed financial vehicle with no viable drug pipeline.
- 2026-05-15 Avoid UPDATE: Gossamer Bio (GOSS) - The Zombie Files Its Q1, and a Class Action Arrives Cash runway is shorter than the debt maturity, the Hail Mary NDA plan does not change the $99M-vs-$198M arithmetic, and a new class action adds liability ahead of equity holders.
- 2026-05-19 Avoid UPDATE: Gossamer Bio (GOSS) - The Debt Wall Comes Down, and So Does the Equity The debt-for-equity exchange triples the float in noteholder hands, forces a mandatory $100-150M equity raise, and leaves common shareholders diluted into a sliver behind $72M of secured first-lien debt.
- 2026-07-28 Avoid UPDATE: Gossamer Bio (GOSS) - The Zombie Gets a Filing Path FDA distinguished filing from review issues giving a non-frivolous NDA pathway, and debt was cut by $115.9M, but cash is down to ~$57M against a $40M monthly covenant, approval remains the less likely outcome, and existing common faces further dilution from a mandatory equity raise.
- 2026-08-14 Avoid UPDATE: Gossamer Bio (GOSS) - The Debt Wall Didn't Move to 2030. It Moved to March. The 2030 notes carry a springing maturity to March 2, 2027 controlled by a single holdout bondholder, the debt wall was relocated not removed, and common sits behind a covenant-mandated dilution funnel with a shorter fuse than previously understood.
- 2026-08-22 Watch UPDATE: Gossamer Bio (GOSS) - Somebody Just Underwrote the Hail Mary A $250M structured placement with $150M committed capital defuses the March 2027 detonator and extends runway into 2028, removing the bankruptcy/wipeout branch, but the drug's efficacy versus Winrevair is unchanged and existing common faces 3-4x dilution.
- 2026-09-09 Watch UPDATE: Gossamer Bio (GOSS) - The Ratio Lands at 1-for-80 The 1-for-80 reverse split with authorized shares cut from 4B to 50M makes the dilution ceiling visible and the vehicle legible, but the drug's efficacy versus Winrevair is unchanged and the March 2027 stub trigger remains unresolved.
- 2026-09-23 Watch UPDATE: Gossamer Bio (GOSS) - The NDA Is In. The Clock Is Running. NDA submission confirmed on schedule, putting the FDA filing-acceptance decision inside the December 31 deadline for the $125M tranche, but the drug's efficacy is unchanged and the $18.9M stub and March 2027 springing maturity remain unresolved.
- 2026-11-11 Watch UPDATE: Gossamer Bio (GOSS) - The Mailroom Bet Becomes a Survival Bet Only $11.2M cushion above the $40M liquidity covenant with ~$84M of debt potentially due in H1 2027 means FDA filing acceptance is now a survival event, not just an upside catalyst; approval remains the less likely outcome.
- Avoid call · opened Mar 2, 2026 at $34.29 · closed Aug 24, 2026 (downgraded to WATCH from avoid) at $14.00 · -59.2% vs XBI +29.7%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (2 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“If the NDA is accepted for filing, seralutinib could be eligible for an FDA approval decision in the third quarter of 2027.”
matched to seralutinib (PAH) · regulatory decision
-
-
-
“Following a Pre-NDA Type B meeting with the FDA held in mid-June 2026 and receipt of the official meeting minutes, we plan to proceed with an NDA submission for seralutinib for the treatment of PAH in September 2026.”
matched to seralutinib (PAH) · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (54)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 15, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026S-3Shelf registration
- Nov 10, 2026ReleaseGossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q lands with both 2027 and 2030 notes classified as current liabilities, cash down to $51.2M against a $40M monthly covenant floor, and the $125M second tranche expiring December 31 — the FDA acceptance clock has never mattered more.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 29, 2026SCHEDULE 13D/A13D amendment
- Oct 28, 20268-KCurrent report: shareholder vote
- Oct 8, 2026SCHEDULE 13D/A13D amendment
- Sep 28, 2026SCHEDULE 13D/A13D amendment
- Sep 28, 20268-KCurrent report: other events
- Sep 23, 2026ReleaseGossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension→ BD updateSummary on the 8-KBD extracted 1 program update from this document → GOSS pipeline
- Sep 23, 20268-KCurrent report: other events→ BD updateGossamer's NDA for seralutinib landed today as forecast — but the stock is down 14.1% since the September 9 split announcement, decoding why the market is unmoved (or skeptical) on what looks like a milestone hit is the editorial angle.
- Sep 16, 2026ReleaseGossamer Bio Appoints Greg Ciongoli to Board of Directors
- Sep 16, 2026DEF 14AProxy statement
- Sep 16, 20268-KCurrent report: officer / director change · EX-99.1
- Sep 11, 2026ReleaseGossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
- Sep 11, 20268-KCurrent report: holder rights modified, charter / bylaws / fiscal year, other events · EX-99.1
- Sep 9, 2026ReleaseGossamer Bio Announces 1-for-80 Reverse Stock Split→ BD updateSummary on the 8-K
- Sep 9, 20268-KCurrent report: other events · EX-99.1→ BD updateGossamer confirmed the reverse split ratio subscribers were waiting for: 1-for-80, landing near the severe end of the authorized range — the mechanical prerequisite for the $125M second tranche and the covenant-mandated equity raise that will define what common holders actually own going forward.
- Sep 4, 2026ReleaseGossamer Bio to Present at Cantor Global Healthcare Conference
- Sep 3, 20268-KCurrent report: charter / bylaws / fiscal year
- Aug 26, 20268-KCurrent report: charter / bylaws / fiscal year
- Aug 24, 2026SCHEDULE 13D/A13D amendment
- Aug 21, 2026ReleaseGossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval→ BD updateSummary on the 8-K
- Aug 21, 20268-KCurrent report: material agreement, unregistered sale of equity, charter / bylaws / fiscal year · EX-99.1→ BD updateGossamer closes a $25M initial tranche today and commits investors to $125M more upon FDA NDA acceptance — a structured lifeline that pushes runway into 2028 and defuses the March 2027 springing maturity trigger, at the cost of another massive equity dilution wave.
- Aug 13, 2026ReleaseGossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
- Aug 13, 20268-KCurrent report: results of operations · EX-99.1
- Aug 13, 202610-QQuarterly report
- Jul 27, 2026ReleaseGossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
- Jul 27, 20268-KCurrent report: material agreement, agreement terminated, results of operations · EX-99.1
- Jul 24, 2026SCHEDULE 13D/A13D amendment
- Jul 15, 20268-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
- Jul 1, 2026SCHEDULE 13D/A13D amendment
- Jul 1, 2026ReleaseGossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
- Jul 1, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Jun 17, 2026ReleaseGossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- Jun 17, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Jun 11, 2026SCHEDULE 13DActivist / >5% holder (13D)
- Jun 9, 2026DEF 14AProxy statement
- Jun 5, 20268-KCurrent report: material agreement, agreement terminated, debt / obligation · EX-99.1
- Jun 5, 20268-KCurrent report: shareholder vote
- Jun 3, 2026ReleaseGossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- Jun 2, 2026ReleaseGossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- Jun 2, 20268-KCurrent report: other events · EX-99.1
- May 18, 2026ReleaseGossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support
- May 18, 2026ReleaseGossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
- May 18, 2026DEFA14AProxy soliciting material
- May 18, 20268-KCurrent report: material agreement, results of operations, officer / director change · EX-99.1
- May 15, 2026ReleaseGossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026
- May 15, 202610-QQuarterly report
- Apr 24, 2026DEFA14AProxy soliciting material
- Apr 24, 2026DEF 14AProxy statement
- Apr 9, 20268-KCurrent report: listing notice
- Mar 17, 20268-KCurrent report: results of operations · EX-99.1
- Mar 17, 202610-KAnnual report
19 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 6, 2026SCHEDULE 13G/A13G amendment
- Nov 6, 2026SCHEDULE 13GPassive >5% holder (13G)
- Sep 4, 2026DForm D (exempt offering)
- Sep 3, 2026PRE 14APRE 14A
- Jul 29, 2026SCHEDULE 13G/A13G amendment
- Jul 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 11, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 11, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 9, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 18, 2026PRE 14APRE 14A
- May 14, 2026SCHEDULE 13G/A13G amendment
- Apr 24, 2026ARSAnnual report to shareholders
- Mar 27, 2026SCHEDULE 13G/A13G amendment
- Mar 24, 2026SCHEDULE 13G/A13G amendment
- Mar 18, 2026EFFECTRegistration effective
- Mar 17, 2026POSASRPOSASR
- Mar 17, 2026POS AMPost-effective amendment
- Mar 2, 2026SCHEDULE 13GPassive >5% holder (13G)